Arrowhead Pharmaceuticals Inc (ARWR NASDAQ) stock market data APIs
$38.3371
-0.53(-1.4%)
as of October 24, 2025
Try our APIs with
free plan!
Arrowhead Pharmaceuticals Inc Financial Data Overview
Price chart is built with
Anychart
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California.
Prev. Close
38.3371
Open
37.8086
High
38.209
Low
37.0316
52 wk Range
9.57-40.289
Market Cap
5 254 M
Shares Outstanding
138 M
Revenue
573 M
EPS
-1.26
Beta
1.137
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Arrowhead Pharmaceuticals Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Arrowhead Pharmaceuticals Inc data using free add-ons & libraries
Get Arrowhead Pharmaceuticals Inc Fundamental Data
Arrowhead Pharmaceuticals Inc Fundamental data includes:
- Net Revenue: 573 M
- EBITDA: -85 396 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-07
- EPS/Forecast: -0.86
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Arrowhead Pharmaceuticals Inc News
New
How Arrowhead’s Evolving Story Is Shaping Analyst Views and Fair Value Targets
Arrowhead Pharmaceuticals has seen its consensus analyst price target increase from $45 to $47.50 per share, reflecting growing confidence in the company's strategy and market positioning. This positi...
Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies Targeting C3, C5, MASP-3, and RNAi | DelveInsight
DelveInsight Business Research LLP The complement 3 glomerulopathy market is poised for steady growth, driven by increasing disease awareness, advances in complement pathway research, and rising diag...
Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
PASADENA, Calif., October 21, 2025--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announ...
Facioscapulohumeral Muscular Dystrophy Analysis Report 2025-2035: Market to Advance Rapidly, Driven by Breakthroughs in Genetic Research, Gene Therapy, and CRISPR-Based Therapeutic Innovations
Company Logo Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder marked by muscle weakness, primarily in the face, shoulders, and arms. The DUX4 gene mutation leads to toxic protein p...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
